Summary
Global Markets Direct’s, ‘Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2016’, provides an overview of the Influenza A Virus, H3N2 Subtype Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections
- The report reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Influenza A Virus, H3N2 Subtype Infections therapeutics and enlists all their major and minor projects
- The report assesses Influenza A Virus, H3N2 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc
AIMM Therapeutics B.V.
Aphios Corporation
Celltrion, Inc.
FluGen, Inc.
Glide Pharmaceutical Technologies Limited
ILiAD Biotechnologies, LLC
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Medicago Inc.
MedImmune, LLC
Mucosis B.V.
NanoViricides, Inc.
OPKO Health, Inc.
Sarepta Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
VBI Vaccines Inc.
Visterra, Inc.
Zydus Cadila Healthcare Limited
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Influenza A Virus, H3N2 Subtype Infections Overview 10
Therapeutics Development 11
Pipeline Products for Influenza A Virus, H3N2 Subtype Infections - Overview 11
Pipeline Products for Influenza A Virus, H3N2 Subtype Infections - Comparative Analysis 12
Influenza A Virus, H3N2 Subtype Infections - Therapeutics under Development by Companies 13
Influenza A Virus, H3N2 Subtype Infections - Therapeutics under Investigation by Universities/Institutes 15
Influenza A Virus, H3N2 Subtype Infections - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Influenza A Virus, H3N2 Subtype Infections - Products under Development by Companies 19
Influenza A Virus, H3N2 Subtype Infections - Products under Investigation by Universities/Institutes 21
Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development 22
AbbVie Inc 22
AIMM Therapeutics B.V. 23
Aphios Corporation 24
Celltrion, Inc. 25
FluGen, Inc. 26
Glide Pharmaceutical Technologies Limited 27
ILiAD Biotechnologies, LLC 28
Inovio Pharmaceuticals, Inc. 29
Johnson & Johnson 30
Medicago Inc. 31
MedImmune, LLC 32
Mucosis B.V. 33
NanoViricides, Inc. 34
OPKO Health, Inc. 35
Sarepta Therapeutics, Inc. 36
Takeda Pharmaceutical Company Limited 37
VBI Vaccines Inc. 38
Visterra, Inc. 39
Zydus Cadila Healthcare Limited 40
Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
APP-0205 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
APP-309 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Aspidasept - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
C-05 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
CR-8020 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
CR-9114 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
CTP-27 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Fluad (quadrivalent) - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
FluGEM - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Gamma-Flu - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
influenza [strain A/H3N2] vaccine - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
influenza [strain A/H3N2] vaccine - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
influenza [strain A/H3N2] vaccine - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
JNJ-872 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
NEO-8877 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
NVINF-1 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
NVINF-2 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
pertussis [strain BPZE1] vaccine - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
PNSIA-28 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
radavirsen - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
REDEE FLU - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
Small Molecules for RSV and Influenza A Infections - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
VIS-410 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects 97
Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones 98
Featured News & Press Releases 98
Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season 98
Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 98
Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza 99
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 101
Disclaimer 102
List of Tables
Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2016 11
Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, H2 2016 22
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AIMM Therapeutics B.V., H2 2016 23
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Aphios Corporation, H2 2016 24
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Celltrion, Inc., H2 2016 25
Influenza A Virus, H3N2 Subtype Infections - Pipeline by FluGen, Inc., H2 2016 26
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016 27
Influenza A Virus, H3N2 Subtype Infections - Pipeline by ILiAD Biotechnologies, LLC, H2 2016 28
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 29
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Johnson & Johnson, H2 2016 30
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Medicago Inc., H2 2016 31
Influenza A Virus, H3N2 Subtype Infections - Pipeline by MedImmune, LLC, H2 2016 32
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Mucosis B.V., H2 2016 33
Influenza A Virus, H3N2 Subtype Infections - Pipeline by NanoViricides, Inc., H2 2016 34
Influenza A Virus, H3N2 Subtype Infections - Pipeline by OPKO Health, Inc., H2 2016 35
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2016 36
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 37
Influenza A Virus, H3N2 Subtype Infections - Pipeline by VBI Vaccines Inc., H2 2016 38
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Visterra, Inc., H2 2016 39
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 40
Assessment by Monotherapy Products, H2 2016 41
Assessment by Combination Products, H2 2016 42
Number of Products by Stage and Target, H2 2016 44
Number of Products by Stage and Mechanism of Action, H2 2016 46
Number of Products by Stage and Route of Administration, H2 2016 48
Number of Products by Stage and Molecule Type, H2 2016 50
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H2 2016 97
List of Figures
Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2016 11
Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Products, H2 2016 18
Assessment by Monotherapy Products, H2 2016 41
Assessment by Combination Products, H2 2016 42
Number of Products by Targets, H2 2016 43
Number of Products by Stage and Targets, H2 2016 43
Number of Products by Mechanism of Actions, H2 2016 45
Number of Products by Stage and Mechanism of Actions, H2 2016 45
Number of Products by Routes of Administration, H2 2016 47
Number of Products by Stage and Routes of Administration, H2 2016 47
Number of Products by Molecule Types, H2 2016 49
Number of Products by Stage and Molecule Types, H2 2016 49
